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Abstract
Background: Mutational analysis of the KRAS gene has recently been established as a complementary in vitro 
diagnostic tool for the identification of patients with colorectal cancer who will not benefit from anti-epidermal growth 
factor receptor (EGFR) therapies. Assessment of the mutation status of KRAS might also be of potential relevance in 
other EGFR-overexpressing tumors, such as those occurring in breast cancer. Although KRAS is mutated in only a minor 
fraction of breast tumors (5%), about 60% of the basal-like subtype express EGFR and, therefore could be targeted by 
EGFR inhibitors. We aimed to study the mutation frequency of KRAS in that subtype of breast tumors to provide a 
molecular basis for the evaluation of anti-EGFR therapies.
Methods: Total, genomic DNA was obtained from a group of 35 formalin-fixed paraffin-embedded, triple-negative 
breast tumor samples. Among these, 77.1% (27/35) were defined as basal-like by immunostaining specific for the 
established surrogate markers cytokeratin (CK) 5/6 and/or EGFR. KRAS mutational status was determined in the purified 
DNA samples by Real Time (RT)-PCR using primers specific for the detection of wild-type KRAS or the following seven 
oncogenic somatic mutations: Gly12Ala, Gly12Asp, Gly12Arg, Gly12Cys, Gly12Ser, Gly12Val and Gly13Asp.
Results: We found no evidence of KRAS oncogenic mutations in all analyzed tumors.
Conclusions: This study indicates that KRAS mutations are very infrequent in triple-negative breast tumors and that 
EGFR inhibitors may be of potential benefit in the treatment of basal-like breast tumors, which overexpress EGFR in 
about 60% of all cases.
Background
Breast cancer is a complex and heterogeneous disease
that includes tumors of variable prognosis and clinical
response to treatments [1]. Standard breast tumor classi-
fication has long relied on morphological and anatomical
criteria such as tumor size and extension (TNM staging),
histopathological features (tumor grade) and expression
of protein markers such as the estrogen receptor (ER),
progesterone receptor (PR) and the human epidermal
growth factor receptor 2 (HER2) oncogene [1,2]. While
these parameters may correlate well with survival in some
patients, their value as prognostic and predictive factors
is limited given the fact that patients with similar tumors
often have a different clinical progression and treatment
response [1,2]. The existence of such differences in the
c l i n i c a l  o u t c o m e  o f  b r e a s t  c a n c e r  p a t i e n t s  c a n  b e
explained by intrinsic tumor variability at the molecular
level [3-7]. In two landmark studies, Perou et al. and Sor-
lie et al. [3,5] identified five distinct "intrinsic" subtypes of
breast cancer by hierarchical cluster analysis of microar-
ray gene expression data: luminal A and luminal B [both
estrogen receptor-positive (ER+)], HER2 overexpressing
(HER2+), normal breast-like and basal-like. These sub-
types are associated with different clinical outcomes, with
the HER2+ and basal-like subtypes being more agressive
and having poor prognoses [5,8]. The term triple-nega-
tive is frequently used as synonymous for basal-like, since
these tumors lack expression of ER, PR and HER2 [9,10].
However, not all triple-negative tumors are basal-like
while most basal-like tumors are triple-negative [4,10].
Triple-negative tumors are found in only 15% of all breast
cancer patients and the incidence varies by race and age.
In particular, the basal subtype represents 10-14% of all
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breast cancers in Caucasian women and 20-37% in Afri-
can American patients [11,12]. Despite their low inci-
dence, triple-negative breast cancer represent a major
clinical challenge due to the high mortality associated
with the disease [4].
At the immunohistochemical level, the basal-like sub-
type express a group of proteins similar to those
expressed in the basal -hence the name- ephithelial cells
of the mammary gland. These include cytokeratins (CK)
5, 6 and 17, epidermal growth factor receptor (EGFR),
caveolin, Ki-67, c-KIT and αβ-crystalin [3,5,13,14]. Most
of basal-like tumors are highly proliferative, show high
histologic grade and are associated with a higher inci-
dence of mutations in BRCA1 and TP53 [15]. Clinically,
these tumors are agressive and tend to form metastasis in
the lungs or in the brain [16,17]. Similar to the HER2+,
the triple-negative subtype shows responsiveness to che-
motherapy with taxanes and anthracyclines [18,19]. It is
typically associated with a bad prognostic, as defined by
reduced disease-free survival (DFS) and overall survival
(OS) rates [16,17]. Hormone therapies and anti-HER2
therapies are innefective in the treatment of triple-nega-
tive breast cancer and thus, searching for new drug tar-
gets selective for this subtype of tumors is a major
challenge in modern oncology.
Near 60% of basal-like tumors express the epidermal
growth factor receptor (EGFR) and, therefore are poten-
tial targets of EGFR inhibitors such as the monoclonal
antibodies cetuximab and panitumumab or the small
molecule inhibitors gefitinib and erlotinib. [20,21]. Sig-
nals initiated at the EGFR are transmited intracellularly
by members of the GTPase Ras family of proteins, which
function as molecular switches in the transduction of
proliferative and differentiating signals [22]. Members of
this family include KRAS, HRAS, NRAS and RRAS, with
KRAS being a mammalian homolog of the Kirsten ras
oncogene [23]. Ras proteins are activated by guanine
nucleotide exchange factors (GEFs), allowing release of
bound GDP and binding of cytosolic GTP. Once acti-
vated, they function at the plasma membrane by recruit-
ing several signaling proteins such as RAF, PI 3-kinase
and RalGDS [24]. The low intrinsinc GTPase activity of
Ras is increased by interaction with GAP (GTPase acti-
vating protein) which hydrolizes bound GTP and turns
off Ras signaling [24]. Several oncogenic mutations have
been described in the KRAS gene wich result in its consti-
tutive activation and in autonomous, non-regulated pro-
liferation of the transformed cells as well as their
resistance to apoptosis [22]. Somatic KRAS mutations are
found in pancreatic cancer (60% of tumors), colon cancer
(32%), lung cancer (17%) and, with a much lower inci-
dence (5%), in leukemias and breast cancer [24]. Ger-
mline mutations in KRAS are associated with Noonan
syndrome and cardio-facio-cutaneous syndrome [25,26].
Anti-EGFR therapies relay on the presence of wild-type
Ras to be effective since oncogenic Ras transmits prolifer-
ative and antiapoptotic signals independently of the
EGFR activation [22,24]. For that reason, treatments with
anti-EGFR drugs such as cetuximab and panitumumab
have incorporated routine assessment of KRAS  status
prior to administration [27]. The effectiveness of EGFR
inhibitors in metastatic colon cancer has been reported in
several studies measuring the response rate (RR) and DFS
[27-35]. Importantly, the effectiveness of both drugs is
limited to those tumors harboring no oncogenic muta-
tions in KRAS [28].
Since most basal-like tumors express EGFR, it seemed
of interest to investigate the mutational status of KRAS in
such tumors to provide scientific evidence for the evalua-
tion of anti-EGFR therapies in the management of triple-
negative breast cancer. Our results indicate that most, if
not all, triple-negative tumors harbor wild-type KRAS,
supporting the use of EGFR inhibitors, alone or in combi-
nation with other drugs, for their treatment.
Methods
Samples
Tumor samples were obtained from 35 patients with early
breast cancer of the basal-like subtype who had under-
gone treatment at the Hospital Clínico Universitario Vir-
gen de la Victoria (HCUVV, Málaga, Spain). Tumors were
classified as basal-like following the criteria stablished by
Nielsen et al., i.e., expression of cytokeratins 5/6 and/or
EGFR together with lack of expression of ER and HER2
[20]. These criteria have demonstrated 76% sensitivity
and 100% specificity for the identification of basal-like
b r e a s t  t u m o r s  a s  d e f i n ed  b y  g e n e  e x p r e s s i o n  p r o f i l i n g.
The corresponding formalin-fixed, paraffin-embedded
tissues were obtained from the Pathology Department at
HCUVV and processed by immunohistochemistry to
check the expression of ER, EGFR and cytokeratins.
T u m o r  a r e a s  w e r e  m a r k e d  b y  d i r e c t  v i s u a l i z a t i o n  i n  5
serial 10-μM-thick sections and manually microdissected
with a razor blade. To obtain genomic DNA, dissected
samples were disolved in xylene to remove paraffin and
processed with the QIAamp DNA FFPE Tissue kit (Qia-
gen) following the manufacturer's instructions. DNA was
quantitated spectrophotometrically by measuring absor-
bance at λ =260 nm in a Nanodrop system. All DNA sam-
ples included in this study had an A260/A280 ratio higher
than 1.8. As a positive control for the mutation analysis,
we also included genomic DNA prepared from two colon
cancer biopsies known to be positive for KRAS mutation.
Experimental procedures were approved by the Scientific
and Ethical Review Board of the HCUVV.Sánchez-Muñoz et al. BMC Cancer 2010, 10:136
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Immunohistochemistry
Immunohistochemical staining was performed on 3-μm
sections of paraffin blocks containing tumour tissue.
HER2 immunohistochemistry was performed following
the instructions included in the HercepTest™ kit (Dako).
For all other antigens, epitopes were retrieved by micro-
waving the sections in citrate buffer pH 6.0 for 20 min.
Immunohistochemistry was carried out in a Tech Mate
Horizon autoimmunostainer (Dako, Copenhagen, Den-
mark) using the Dako Real EnVision system for signal
detection. The following antibodies were from Dako:
estrogen receptor (clone 1D5), progesterone receptor
(clone PgR636) and HER2 (HercepTest™). The anti-CK5/6
antibody (clone D5/16B4) was from Boehringer Bio-
chemica). EGFR expression was determined with the
EGFR pharmaDx™ kit for autostainer (Dako). For ER and
PR immunoreactivity, the cut-off value of 10% was used
to divide cases into negative and positive groups. HER2
expression was scored following the guidelines of the
HercepTest™ kit and interpreted as negative when the
staining intensity was 0 or 1+ and positive when it was 2+
or 3+. Membrane staining was used as the evaluable
parameter to determine EGFR expression with the EGFR
pharmaDx™ kit. Positivity for EGFR expression was
defined as any membrane staining above background
level in at least 1% of tumor cells. Absence of staining was
reported as negative. For the basal marker CK 5/6, posi-
tivity was defined as detection of any stained invasive
malignant cells.
Mutation analysis
The Therascreen KRAS kit (Roche Diagnostics) was used
to determine the mutational status of KRAS in the sam-
ples. Briefly, 50-100 ng of total genomic DNA was ana-
lyzed by Real Time (RT)-PCR using mutation-specific
Scorpions® primers. The kit allowed detection of the fol-
lowing mutations: Gly12Ala (GGT>GCT)522, Gly12Asp
(GGT>GAT)521, Gly12Arg (GGT>CGT)518, Gly12Cys
(GGT>TGT)516, Gly12Ser (GGT>AGT)517, Gly12Val
(GGT>GTT)520, Gly13Asp (GGC>GAC)532. All experi-
ments included both a positive (each mutant DNA) and a
negative (no template) control reaction. Reactions were
carried out in 96-well plates in an ABI 7500 Real-Time
PCR system (Applied Biosystems). Threshold cycle (Ct)
was plotted against normalized reporter (Rn) and the ΔCt
was calculated by the formula: ΔCt = Cts-Ctc, were Cts and
Ctc are the Ct of the sample and the positive control,
respectively. Values of Ctc were in the range of 29-35. The
obtained ΔCt values were compared with the reference
values provided in the kit to classify the samples as posi-
tive or negative for each KRAS mutation.
Results and discussion
Thirty-five archived paraffin blocks containing tumor
samples from different breast cancer patients were ini-
tially selected as triple-negative on the basis of their lack
of immunoreactivity for the surrogate markers ER, PR
and HER2 (Table 1 and Fig. 1). We then performed addi-
tional immunostaining with antibodies against CK5/6
and EGFR to identify the subgroup of basal-like tumors
[20]. Such analysis revealed that 77.1% (27/35) of the
tumors were basal-like. Table 2 summarizes the immuno-
histological characteristics of all tumors analyzed in this
study. Expression of CK5/6 was detected in 63.0% of all
tumors classified as basal-like while 92.6% stained posi-
tive for EGFR (Table 2). The observed proportion of
basal-like tumors expressing CK5/6 is in good agreement
with that reported by other groups [9,20] however, we
found a higher frequency of EGFR expression when com-
pared with the 57% and 27% values reported by Nielsen et
al. [20] and Kreike et al. [9], respectively. Of note, the
EGFR status in breast cancer has not been examined as
extensively as in other types of cancer and its reported
overexpression ranges from 14% to 91% [36-38]. EGFR
expression has been associated with BRCA1-mutated
tumors and basal-like phenotype in several studies
[37,39-41]. In addition, some observations suggest that
EGFR upregulation is an early event in breast tumorigen-
esis since EGFR overexpression can be observed in pre-
malignant lesions [37]. As has been suggested by some
investigators, a more detailed study on the activation sta-
tus and subcellular localization of wild-type EGFR, in
both primary and metastatic tumors, is needed to evalu-
ate EGFR expression as a predictive marker for response
to anti-EGFR therapies [42].
Although the subtyping of our group of 35 tumor sam-
ples did not emerged from gene expression profiling data,
they were defined as triple-negative (nonbasal) or basal-
like by immnostaining with a set of four surrogate mark-
ers that has been demonstrated to be 76% sensitive and
100% specific [20]. Here, we will use the term triple-nega-
tive in reference to the full set of 35 tumor samples (ER-,
PR- and HER2-) while the term basal-like will be reserved
for the subset of samples that, in addition to being ER-,
PR- and HER2-, are positive for CK5/6 and/or EGFR
staining.
Breast cancer cell lines stablished from basal-like
tumors are more sensitive to EGFR inhibitors and carbo-
platin -alone or in combination- than those stablished
from luminal tumors [32]. Both drugs have an additive
effect when added in combination [32] and preclinical
data argue in favor of anti-EGFR therapies in this subtype
of tumors. Oncogenic Ras proteins can signal cell prolif-
eration even in the absence of EGFR activation and thus,
molecular testing of human KRAS mutations is of great
relevance in the identification of patients that may benefit
from anti-EGFR therapies. In a study reported by Holles-
telle et al. [43]KRAS mutations were found in 5 out of 40
different breast cancer cell lines (13% incidence). Overall,
KRAS mutations are infrequent in breast cancer, repre-Sánchez-Muñoz et al. BMC Cancer 2010, 10:136
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Table 1: Immunohistochemical data.
Sample # ID CK5/6* EGFR* Basal-like=
1 757688 - + yes
2 767740 + + yes
3 832343 - + yes
4 608891 + + yes
5 857666 + - yes
6 804529 + + yes
7 555943 + + yes
8 452803 - + yes
9 481252 + + yes
10 222867 - - no
11 402341 - + yes
12 760011 + + yes
13 834492 - + yes
14 778794 - - no
15 717674 + + yes
16 768943 - - no
17 438696 - + yes
18 CH + + yes
19 198346 + + yes
20 853477 + + yes
21 265886 - - no
22 841511 + + yes
23 708805 - + yes
24 856202 - + yes
25 841511 + + yes
26 852333 + + yes
27 405573 + - yes
28 194302 - - no
29 108707 - - no
30 43742 + + yes
31 560504 - - no
32 779157 - + yes
33 107512 - - no
34 772351 - + yes
35 844953 + + yes
*positivity detected by immunohistochemistry
=basal-like = CK5/6+ and/or EGFR+
Abbreviations: ID, identificationSánchez-Muñoz et al. BMC Cancer 2010, 10:136
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senting a mere 5% of all breast carcinomas [24]. However,
it is not known if they are distributed randomly in all five
molecular subtypes of breast cancer (luminal A, luminal
B, HER2+, normal-like and basal-like) or concentrated in
one or a few subtypes. In particular, ~60% of the basal-
like tumors express EGFR and thus, they are an attractive
target for EGFR inhibitors. Thus, we wanted to investi-
gate if molecular testing of KRAS mutations would serve
as a prognostic factor in adjuvant therapy recommenda-
tions for basal-like breast cancer patients.
T o that aim, total genomic DNA obtained from each
paraffin-embedded tumor was subjected to RT-PCR
reactions with primers specifically designed to amplify
and detect seven cancer-related somatic mutations in
codons 12 and 13 of human KRAS [44,45]. Notably, none
of the DNA samples could function as template for
amplification of the KRAS oncogenic mutations, indicat-
ing that the full set of 35 triple-negative tumors expressed
the wild-type protein (Table 2 and Fig. 2). As such, the
wild-type KRAS gene could be amplified and detected in
all 35 DNA samples. Also, genomic DNA from a colon
carcinoma known to harbor a Gly12Cys mutation in
KRAS could be amplified and the mutation detected by
R T - PC R  ( F i g.  2 ) .  T h i s  r e s u l t  i n d i c a t e s  t h a t  t h e  l a c k  o f
KRAS mutations observed in the breast tumor samples
were not due to a deficiency in the assay (Fig. 2). There-
fore, we found no evidence of KRAS somatic mutations in
human triple-negative tumors as measured by a standa-
rized assay [44,45]. We cannot exclude the possibility that
a minimal number of cells, below the detection limit of
the assay (< 1% of tumor cells) harbor mutations in KRAS,
however, we used the same diagnostic assay currently
included in the clinical practice to select colorectal
patients for anti-EGFR treatments. It is well known that
KRAS mutations are infrequent in breast cancer [24] and
our data further indicates that they are not distributed
homogeneously and are uncommon, if not absent, in tri-
ple-negative tumors. In a recent study aimed at the iden-
tification of EGFR-associated expression profiles in
different breast cancer subtypes, Perou and co-workers
mentioned that, as a control, they sequenced 96 breast
tumors and found no common mutations in BRAF, HRAS
and KRAS [32]. While our results are in agreement with
such findings, they represent, to the best of our knowl-
edge, the first attempt to directly determine the incidence
of KRAS mutations in basal-like breast tumors and to dis-
cuss them in the context of anti-EGFR therapies.
Two randomized phase II trials have evaluated the role
of cetuximab in triple negative breast cancer. In the
TBCRC 001 study, eligible, pretreated patients received
the anti-EGFR monoclonal antibody cetuximab alone,
with planned crossover to cetuximab plus carboplatin
upon progression (arm 1) or cetuximab combined with
carboplatin from the very begining (arm 2). Monotherapy
with cetuximab showed low clinical benefit (CB) and RR
(10% and 6%, respectively) and was cancelled early due to
lack of efficacy. Moreover, the combination of cetuximab
plus carboplatin achieved a modest activity: 17% RR, and
31% CB [46]. A different phase II trial showed a higher RR
in triple-negative patients treated with the combination
of irinotecan plus carboplatin and cetuximab versus
those treated with irinotecan plus carboplatin (49% vs
30%) [46]. Both trials included unselected patients with
heavily pretreated tumors. It should be noted that
although most basal-like cancers do not express ER and
HER2, 15% to 45% are reported to express at least one of
these markers. On the other hand, not all triple negative
cancers are of basal-like profile, only approximately 85%
of ER- and Her2- cancers are classified as basal-like by
microarray analysis [20].
Besides KRAS, alterations in the phosphatidylinositol
3-kinase (PI3K) pathway have been described in several
types of cancer [47,48]. In particular, activating mutations
in  PIK3CA, the gene encoding for the p110α catalytic
subunit of PI3K, confers resistance to cetuximab-induced
cell cycle arrest in colon cancer cell lines [49]. The cells
are maximally resistant when KRAS  and  PIK3CA  are
mutated simultaneously [49]. The PIK3CA mutation fre-
q u e n cy  i n  b r e a s t  c a n c e r  r e p o r t e d l y  v a r i e s  b e t w e e n  8 %
and 40% [50-53]. Kalinsky et al. found PI3KCA mutations
in 32.5% of invasive breast primary tumors in a large
cohort of 590 samples [52] and, interestingly they corre-
lated with older age at diagnosis, lower tumor grade and
stage, and lymph node negativity. In addition, patients
with  PIK3CA  mutations had improved OS and breast
cancer-specific survival [52]. In a different study with a
smaller cohort of 292 breast cancer patients, activation of
the PI3K pathway (by genetic alterations in the PIK3CA,
PTEN or AKT genes) was found to be significantly associ-
ated with a basal-like phenotype, high tumor grade and
Table 2: Frequency of immunostaining and KRAS mutations among breast cancer tumors.
Subtype Samples CK5/6+ (%) EGFR+ (%) CK/EGFR+ (%)* KRAS mut (%)
TN 35 17 (48.6) 25 (71.4) 15 (42.8) 0 (0.0)
BS 27 17 (63.0) 25 (92.6) 15 (55.5) 0 (0.0)
*Positive staining for both CK5/6 and EGFR
Abbreviations: TN, triple-negative; BS, basal-like; CK, cytokeratin 5/6; KRAS mut, mutant KRASSánchez-Muñoz et al. BMC Cancer 2010, 10:136
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death from breast cancer. However, PIK3CA mutations
alone did not correlate with any clinicopathological
parameter [54]. Other studies have also reported contra-
dictory -both favorable and poor- patient outcomes asso-
ciated with PIK3CA mutations in breast cancer [51,55].
While we have not addressed the mutational status of the
PI3K pathway, the results from Kalinsky et al. suggest that
activating mutations in PIK3CA will not confer resistance
to anti-EGFR therapies. In fact, mutant cancer cells could
be more sensitive to these type of agents. Alternatively,
Figure 1 Representative immunohistochemistry of a basal-like breast tumor showing negative staining for the hormone receptors (ER and 
PR) and HER2 and positive staining for EGFR and CK5/6.Sánchez-Muñoz et al. BMC Cancer 2010, 10:136
http://www.biomedcentral.com/1471-2407/10/136
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Figure 2 Detection of KRAS mutations by RT-PCR. A, The graph shows a representative amplification curve (ΔRn vs cycle) from 100 ng of genomic 
DNA prepared from a triple-negative tumor sample. RT-PCR reactions were performed with primers specifically designed to amplify wild-type KRAS 
(red) or the following mutants: Gly12Ala (green), Gly12Asp (blue), Gly12Arg (yellow), Gly12Cys (Pink), Gly12Ser (brown), Gly12Val (purple), Gly13Asp 
(grey). Brown lines correspond to the amplification profile of an internal control included in each reaction to check for false positives. B, As a positive 
control, genomic DNA was obtained from a colon carcinoma biopsy and subjected to RT-PCR as in A. Note the presence of the Gly12Cys mutation.Sánchez-Muñoz et al. BMC Cancer 2010, 10:136
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identifying PIK3CA activating mutations in older
patients could benefit them by minimizing the therapy.
Additional studies are needed to clarify this issues.
In summary, despite the fact that most basal-like
tumors included in our study expressed EGFR, we found
no evidence of oncogenic mutations in KRAS. Therefore,
we conclude that testing for KRAS mutations is not nec-
essary as a diagnostic factor in the treatment of basal-like
breast cancer. Furthermore, the wild-type status of KRAS
observed in all samples analyzed here indicate that anti-
EGFR therapeutic strategies, such as those using mono-
clonal antibodies (cetuximab, panitumumab) or small
molecule inhibitors (gefitinib, erlotinib), may be of poten-
tial benefit in the treatment of basal-like breast cancer.
Conclusions
Since we found no incidence of oncogenic KRAS muta-
tions in basal-like tumors, our results indicates that ther-
apies based on EGFR inhibition may be of benefit in the
treatment of this particularly agressive subtype of breast
tumors.
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